根除幽门螺杆菌感染失败与CYP2C19基因变异关系的研究被引量：1

Study the relationship between eradication of Helicobacter Pylori infection and CYP2C19 genetic mutation

下载PDF

导出

摘要目的探讨根除幽门螺杆菌(Hp)感染失败与CYP2C19基因变异关系。方法收集本院诊断为慢性胃炎、胃溃疡和反流性食管炎经标准奥美拉唑三联治疗失败60例,以CYP2C19基因型分组,再以埃索美拉唑三联治疗1周后复查14C,并判断Hp根除情况。结果 60例Hp根除失败患者可分为CYP2C19基因强代谢型和弱代谢型两组,组间年龄、病种、性别比较差异无统计学意义,民族分布差异有统计学意义。经埃索美拉唑三联治疗后,CYP2C19强代谢型组Hp根除率为93.9%,弱代谢型组Hp根除率为100%,两组患者Hp根除无统计学意义。结论根除Hp感染失败与CYP2C19基因变异关系紧密。 Objective To analyze the relationship between eradicate of Helicobacter pylori infection and CYP2C19 genetic mutation. Methods All of 60 patients diagnosed chronic gastritis,gastric ulcer or reflux esophagitis who underwent stan- dard omeprazole triple therapy and failed to eradicate Hp in our hospital were enrolled in our study.CYP2C19 genotypes separated 60 cases into two groups.Then esomeprazole triple therapy was applied for 1 week.After treatment, 14C-urea breath test was done to determine the Hp eradication situation. Results All of 60 patients with failure Hp eradication with CYP2CI9 gene were divided into strong and weak metabolic type groups.Age,disease type had no significant differences, while ethnic distribution has differences.After esomeprazole triple therapy,CYP2C19 strong metaholizers＇Hp eradication rate was 93.9% ,weak metabolizers＇ 100%.There was no difference for two group＇s Hp eradication rates. Conclusion Fail- ure eradication of Helicobactcr pylori infection and CYP2C 19 genetic mutation are closely related.

作者缪杨德

机构地区浙江省台州市立医院消化科

出处《中国现代医生》 2012年第10期145-146,148,共3页 China Modern Doctor

关键词根除幽门螺杆菌:CYP2C19 变异 Eradication of Helicobacter Pylori CYP2C19 Mutation

分类号 R573.3 [医药卫生—消化系统]

引文网络
相关文献

参考文献7

1Jinda S,Nakatani K,Nishioka J. Personalized treatment in the eradication therapy for Helicobacter pylori[J]. Int J Mol Med ,2011,27(2) :255-261.
2Miehlke S,Lobe S, Madisch A. lntragastric acidity during administration of gent, rio omeprazole or esomeprazole-a randomised, two-way crossover study including CYP2C19 genotyping [J]. Aliment Pharmaco] Ther, 2011,33(4) :471-476.
3Yang JC,Wang HL,Chern HD. Role of omeprazole dosage and cy tochrome P450 2C19 genotype in patients reeeiving omeprazole-amoxi cillin dual therapy for Helicobacter pylori eradication[J]. Pharmacother apy, 2011,31 (3) : 227-238.
4Ward MB,Foster DJ. CYP2C19-guided design of a proton pump in-hibitor dose regimen to avoid the need for pharmacogenetic individual- ization in H. pylori eradication[J]. Eur J Clin Pharmacol,2011,67(3) :261 - 266.
5Liou JM,Chen CC,Chen MJ. Empirical modified sequential therapy con- taining levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection :a multicentre clinical trial[J]. J Antimicrob Chemother, 2011,66(8) : 1847-1852.
6Lee VW,Chau TS,Chan AK. Pharmacogenetics of esomeprazole orrabeprazole-based triple therapy in Helicobaeter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects[J]. J Clin Pharm Ther, 2010,35 (3) : 343-350.
7Kesavan R,Narayan SK,Adithan C. Influence of CYP2C9 and CYP2CI9 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients[J].Eur J Clin Pharmacol, 2010,66 (7) : 689- 696.